Wells Fargo’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $594K | Buy |
52,131
+9,301
| +22% | +$106K | ﹤0.01% | 3669 |
|
|
2025
Q1 | $509K | Buy |
42,830
+3,551
| +9% | +$42.2K | ﹤0.01% | 3672 |
|
|
2024
Q4 | $740K | Sell |
39,279
-1,524
| -4% | -$28.7K | ﹤0.01% | 3463 |
|
|
2024
Q3 | $917K | Buy |
40,803
+15,454
| +61% | +$347K | ﹤0.01% | 3255 |
|
|
2024
Q2 | $529K | Buy |
25,349
+4,182
| +20% | +$87.3K | ﹤0.01% | 3546 |
|
|
2024
Q1 | $311K | Buy |
21,167
+2,011
| +10% | +$29.6K | ﹤0.01% | 3844 |
|
|
2023
Q4 | $198K | Sell |
19,156
-14,890
| -44% | -$154K | ﹤0.01% | 4088 |
|
|
2023
Q3 | $268K | Sell |
34,046
-5,967
| -15% | -$46.9K | ﹤0.01% | 3881 |
|
|
2023
Q2 | $400K | Buy |
40,013
+6,583
| +20% | +$65.8K | ﹤0.01% | 3897 |
|
|
2023
Q1 | $297K | Buy |
33,430
+31,730
| +1,866% | +$282K | ﹤0.01% | 3940 |
|
|
2022
Q4 | $18.7K | Sell |
1,700
-926
| -35% | -$10.2K | ﹤0.01% | 4974 |
|
|
2022
Q3 | $34K | Sell |
2,626
-334
| -11% | -$4.32K | ﹤0.01% | 4816 |
|
|
2022
Q2 | $38K | Sell |
2,960
-7,766
| -72% | -$99.7K | ﹤0.01% | 4873 |
|
|
2022
Q1 | $150K | Sell |
10,726
-10,230
| -49% | -$143K | ﹤0.01% | 4814 |
|
|
2021
Q4 | $607K | Buy |
20,956
+6,402
| +44% | +$185K | ﹤0.01% | 4224 |
|
|
2021
Q3 | $437K | Buy |
14,554
+14,234
| +4,448% | +$427K | ﹤0.01% | 4468 |
|
|
2021
Q2 | $9K | Sell |
320
-13,495
| -98% | -$380K | ﹤0.01% | 5845 |
|
|
2021
Q1 | $430K | Sell |
13,815
-33,692
| -71% | -$1.05M | ﹤0.01% | 4469 |
|
|
2020
Q4 | $1.56M | Buy |
47,507
+12,261
| +35% | +$403K | ﹤0.01% | 3619 |
|
|
2020
Q3 | $1.23M | Buy |
+35,246
| New | +$1.23M | ﹤0.01% | 3622 |
|